Does Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide Interact with Drugs Competing For Active Tubular Secretion?
CDI records a moderate classification for Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and Drugs Competing For Active Tubular Secretion. The stored summary is: Co-administration may increase concentrations of emtricitabine and tenofovir, increasing risk of adverse reactions. The mechanism involves competition for renal tubular secretion or reduced renal function. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide Class
- Cytochrome P450 3A Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Competition for renal tubular secretion or reduced renal function
What To Tell Your Doctor or Pharmacist
If you are taking Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and your doctor is considering prescribing Drugs Competing For Active Tubular Secretion (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider